NCT06372717 - A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

April 1, 2027

Conditions

Acute Myeloid Leukemia RefractoryMyelodysplastic Syndrome Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess BlastsAcute Myeloid Leukemia, in Relapse

Interventions

DRUG

APL-4098

APL-4098 is administered orally in 28-day cycles

DRUG

Azacitidine and APL-4098

Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.

Trial Locations (7)

3004

RECRUITING

The Alfred Hospital, Melbourne

3065

RECRUITING

St. Vincent's Hospital Melbourne, Fitzroy

3168

RECRUITING

Monash Health, Clayton

6000

RECRUITING

Royal Perth Hospital, Perth

6009

RECRUITING

Hollywood Private Hospital, Nedlands

SM2 5PT

RECRUITING

The Royal Marsden Hospital, London

W1G 0PU

RECRUITING

Sarah Cannon Research Institute UK, London